306935-14-8

Usage

Uses

Used in Pharmaceutical Industry:
3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE is used as a pharmaceutical intermediate for the synthesis of various drugs due to its potential pharmacological activities.
Used in Antimicrobial Applications:
3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE is used as an antimicrobial agent for its ability to combat various microorganisms, contributing to the development of new antibiotics and antimicrobial drugs.
Used in Anticonvulsant Applications:
3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE is used as an anticonvulsant agent, potentially helping in the management and treatment of seizure disorders.
Used in Antidepressant Applications:
3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE is used as an antidepressant agent, potentially aiding in the treatment of mood disorders and depression.
Used in Antitumor Applications:
3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE is used as an antitumor agent, showing promise in the development of cancer therapeutics due to its potential to inhibit tumor growth and progression.

InChI:InChI=1/C12H14N4S/c1-2-4-10(5-3-1)11-14-12(17-15-11)16-8-6-13-7-9-16/h1-5,13H,6-9H2

Upstream product

• 887623-99-6 tert-butyl 4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxylate 
• 1670-14-0 benzamidine monohydrochloride 
• 24255-23-0 5-chloro-3-phenyl-[1,2,4]thiadiazole 
• 110-85-0 piperazine 
• 594-42-3 chlorothio-trichloro-methane 

Downstream Products

• 331767-52-3 9-{4-[4-(3-phenyl-[1,2,4]thiadiazol-5-yl)-piperazin-1-yl]-butyl}-9H-fluorene-9-carboxylic acid-(2,2,2-trifluoroethyl)-amide 
• 874646-44-3 (5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[4-(3-phenyl-1,2,4-thiadiazol-5-yl)-1-piperazinyl]carbonyl}butyl)-1,3-dioxolan-4-one 
• 681136-29-8 N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide 

Relevant academic research and scientific papers

The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119

A series of xanthine compounds derived from the previous hit 20i with modification on the terminal side chain was discovered through ring formation strategy. Systematic optimization of the compounds with rigid heterocycles in the hydrophobic side chain led to the new lead compound HBK001 (21h) with the improved DPP-IV inhibition and moderate GPR119 agonism activity in vitro. As a continuing work to further study the PK and PD profiles, 21h and its hydrochloride (22) were synthesized on grams scale and evaluated on the ADME/T and oral glucose tolerance test (OGTT) in ICR mice. Compound 22 showed the improved bioavailability and blood glucose-lowering effect in vivo compared to its free base 21h probably attributed to its improved solubility and permeability. The preliminary toxicity studies on compound 22 exhibited that the result of mini-Ames was negative and the preliminary acute toxicity LD50 in mice was above 1.5 g/kg, while it showed moderate inhibition on hERG channel with IC50 4.9 μM maybe due to its high lipophilicity. These findings will be useful for the future drug design for more potent and safer dual ligand targeting DPP-IV and GPR119 for the treatment of diabetes.

Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors

A series of piperazine ureas was designed, synthesized, and evaluated for their potential as novel orally available fatty acid amide hydrolase (FAAH) inhibitors that are therapeutically effective against pain. We carried out an optimization study of the l

Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase

A series of thiadiazolopiperazinyl aryl urea fatty acid amide hydrolase (FAAH) inhibitors is described. The molecules were found to inhibit the enzyme by acting as mechanism-based substrates, forming a covalent bond with Ser241. SAR and PK properties are

N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase

Certain N-heteroarylpiperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid